-
Changshan Pharmaceutical Holding’S Subsidiary 1.1 Class New Drug Albenatide Starts Phase Iii Clinical Trial
At present, the company has completed the relevant work of Phase II clinical research and preparation of Phase III clinical trial of Albenatide injection. According to the preliminary clinical trial results and clinical trial approval requirements of Albenatide injection, combined with the actual...Read more
